
Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Tyra Bioscience, retaining the price target of $27.00. Mitchell Kapoor’s rating is based on several factors, including dabogratinib’s potential
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TYRA | Tyra Bioscience | 19.60 | 2.99 | 17.99% |
| Name | Price | % Change | |
|---|---|---|---|
| $19.60 | +17.99% |

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Tyra Bioscience, retaining the price target of $27.00. Mitchell Kapoor’s rating is based on several factors, including dabogratinib’s potential

JonesTrading analyst Boris Peaker maintained a Buy rating on Tyra Bioscience today and set a price target of $56.00. Boris Peaker’s rating is based on meaningful progress across Tyra Bioscience’s

H.C. Wainwright lowered the firm’s price target on Tyra Biosciences (TYRA) to $27 from $29 and keeps a Buy rating on the shares. The company’s next clinical updates are initial

As of September 30, Tyra had cash, cash equivalents and marketable securities of $700.5M. Following its September 2026 financing, the Company expects its current financial resources to fund planned operations

Tyra Bioscience, Inc (TYRA) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Tyra Bioscience, Inc to post earnings of -$0.67 per share.

Raymond James added Climb Bio (CLYM) to the firm’s “Analysts Current Favorites” list while removing Tyra Biosciences (TYRA). Climb’s setup for both its lead assets – CLYM116 and budoprutug –

Oppenheimer lowered the firm’s price target on Tyra Biosciences (TYRA) to $40 from $50 and keeps an Outperform rating on the shares. While SURF302 fell short of the firm’s ablative

H.C. Wainwright lowered the firm’s price target on Tyra Biosciences (TYRA) to $29 from $30 and keeps a Buy rating on the shares. The firm cites dilution from the recent

Tyra Bioscience ( ($TYRA) ) just unveiled an update. On September 14, 2026, Tyra Biosciences priced an underwritten offering of 9,079,000 shares of common stock and pre-funded warrants for 9,078,529

Tyra Biosciences (TYRA) announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 17, 2026 | ||||
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Sep 23, 2026 | ||||
| buy | Reiterated | Sep 11, 2026 | ||||
| buy | Reiterated | Sep 9, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 24, 2027TBA | $1.35B | $-0.72 | $0.00 | -0.40 | -7.43 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.